Efficacy of Rapid Salivary C-Reactive Protein Test to Assess Early Changes in Malignancy in the Oral Cavity and Its Utility in Screening for Oral Cancer

Overview

Journal Dent J (Basel)

Date 2025 Jan 24

PMID 39851610

Authors

Vathsala Patil

Ravindranath Vineetha

Komal Smriti

Kalyana Chakravarthy Pentapati

Srikanth Gadicherla

Carnelio Sunitha

Affiliations

Soon will be listed here.

Abstract

The present study aimed to test the efficacy of the chair-side rapid salivary C-reactive protein assay kit in differentiating oral potentially malignant disorders (OPMDs) and oral cancer from normal mucosa using whole salivary samples. In this study, unstimulated saliva samples of cases (OPMDs and oral cancer) and controls (systemically healthy subjects) were used to detect CRP levels using a novel colorimetric, quantitative rapid assay kit. Kruskal-Wallis ANOVA with a post hoc Dunn's test were applied to determine the difference in the mean and SD values between the case and control groups. ROC analysis was performed to identify the positive and negative likelihood ratios. The mean calculated salivary CRP level in the oral cancer group was 4.21 ng/mL, in the OPMD group it was 2.51 ng/mL and in the healthy controls it was 0.7 ng/mL. Post hoc tests showed that the salivary CRP levels were significantly higher in the oral cancer and OPMD groups than in the controls. The present study showed that the novel rapid salivary test kit could significantly differentiate between the salivary CRP values of cases and controls but there was no significant difference between the OPMD and malignancy groups. It also showed higher sensitivity values, confirming the efficacy of this kit as a screening tool.

References

Desai G, Mathews S . Saliva as a non-invasive diagnostic tool for inflammation and insulin-resistance. World J Diabetes. 2014; 5(6):730-8. PMC: 4265859. DOI: 10.4239/wjd.v5.i6.730. View

Sato J, Goto J, Murata T, Kitamori S, Yamazaki Y, Satoh A . Changes in saliva interleukin-6 levels in patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 110(3):330-6. DOI: 10.1016/j.tripleo.2010.03.040. View

Warnakulasuriya S, Johnson N, van der Waal I . Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007; 36(10):575-80. DOI: 10.1111/j.1600-0714.2007.00582.x. View

Out D, Hall R, Granger D, Page G, Woods S . Assessing salivary C-reactive protein: longitudinal associations with systemic inflammation and cardiovascular disease risk in women exposed to intimate partner violence. Brain Behav Immun. 2012; 26(4):543-51. PMC: 3334360. DOI: 10.1016/j.bbi.2012.01.019. View

Mahmood H, Shaban M, Indave B, Santos-Silva A, Rajpoot N, Khurram S . Use of artificial intelligence in diagnosis of head and neck precancerous and cancerous lesions: A systematic review. Oral Oncol. 2020; 110:104885. DOI: 10.1016/j.oraloncology.2020.104885. View

Jablonska E, Piotrowski L, Grabowska Z . Serum Levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in Patients with Oral Cavity Cancer. Pathol Oncol Res. 1997; 3(2):126-129. DOI: 10.1007/BF02907807. View

Ramavath C, Katam S, Vardhelli V, Deshabhotla S, Oleti T . Examining the Utility of Rapid Salivary C-Reactive Protein as a Predictor for Neonatal Sepsis: An Analytical Cross-Sectional Pilot Study. Diagnostics (Basel). 2023; 13(5). PMC: 10000952. DOI: 10.3390/diagnostics13050867. View

Davidson J, Wang J, Maruthamuthu M, Dextre A, Pascual-Garrigos A, Mohan S . A paper-based colorimetric molecular test for SARS-CoV-2 in saliva. Biosens Bioelectron X. 2021; 9:100076. PMC: 8364207. DOI: 10.1016/j.biosx.2021.100076. View

Brailo V, Vucicevic-Boras V, Lukac J, Biocina-Lukenda D, Zilic-Alajbeg I, Milenovic A . Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer. Med Oral Patol Oral Cir Bucal. 2011; 17(1):e10-5. PMC: 3448188. DOI: 10.4317/medoral.17323. View

10.

Pay J, Shaw A . Towards salivary C-reactive protein as a viable biomarker of systemic inflammation. Clin Biochem. 2019; 68:1-8. DOI: 10.1016/j.clinbiochem.2019.04.006. View

11.

Metgud R, Bajaj S . Altered serum and salivary C-reactive protein levels in patients with oral premalignant lesions and oral squamous cell carcinoma. Biotech Histochem. 2015; 91(2):96-101. DOI: 10.3109/10520295.2015.1077393. View

12.

Izawa S, Miki K, Liu X, Ogawa N . The diurnal patterns of salivary interleukin-6 and C-reactive protein in healthy young adults. Brain Behav Immun. 2012; 27(1):38-41. DOI: 10.1016/j.bbi.2012.07.001. View

13.

Gosavi S, Torkadi A . Serum C-reactive protein in oral submucous fibrosis and oral squamous cell carcinoma: A cross-sectional study. J Oral Maxillofac Pathol. 2020; 24(1):46-51. PMC: 7269289. DOI: 10.4103/jomfp.JOMFP_317_19. View

14.

Khandavilli S, O Ceallaigh P, Lloyd C, Whitaker R . Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol. 2009; 45(10):912-4. DOI: 10.1016/j.oraloncology.2009.03.015. View